Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study(Nature Medicine, 10.1038/s41591-024-02986-9)

Franck Morschhauser, Saurabh Dahiya, M. Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S. Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan SkarbnikSven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J. Nastoupil

Research output: Contribution to journalComment/debate

2 Scopus citations

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-02986-9, published online 3 June 2024. In the version of the article initially published, in the Japan row of Supplementary Fig. 2, the values for the columns “Evaluable patients” and “Patients with ORR” were originally both 8 but have now been amended to 9. A corrected Supplementary Information file has now been uploaded online.

Original languageEnglish
Pages (from-to)2374
Number of pages1
JournalNature medicine
Volume30
Issue number8
DOIs
StatePublished - Aug 2024

Fingerprint

Dive into the research topics of 'Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study(Nature Medicine, 10.1038/s41591-024-02986-9)'. Together they form a unique fingerprint.

Cite this